Denali Therapeutics Inc.
DNLI
$19.00
$1.166.50%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -498.74M | -479.03M | -453.94M | -422.77M | -427.49M |
| Total Depreciation and Amortization | 5.75M | 4.16M | 2.14M | 1.09M | 8.55M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 89.53M | 83.00M | 75.44M | 57.05M | 44.08M |
| Change in Net Operating Assets | 5.69M | 42.26M | 10.81M | 16.94M | 12.23M |
| Cash from Operations | -397.78M | -349.62M | -365.54M | -347.69M | -362.64M |
| Capital Expenditure | -13.07M | -18.33M | -18.84M | -15.91M | -13.06M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 419.79M | 460.88M | 402.02M | -72.84M | -174.86M |
| Cash from Investing | 406.72M | 442.55M | 383.18M | -88.76M | -187.92M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -16.48M | -39.13M | -36.70M | -32.34M | -24.02M |
| Issuance of Common Stock | 9.39M | 14.26M | 16.96M | 517.12M | 517.67M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | 0.00 | -480.00K | -480.00K |
| Cash from Financing | -7.09M | -24.87M | -19.73M | 484.30M | 493.18M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.86M | 68.06M | -2.10M | 47.85M | -57.38M |